The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Subscribe To Our Newsletter & Stay Updated
